Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 167, Issue 5, pp 637–640 | Cite as

Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

  • G. B. KolyvanovEmail author
  • V. P. Zherdev
  • O. G. Gribakina
  • P. O. Bochkov
  • R. V. Shevchenko
  • A. A. Litvin
  • E. V. Blynskaya
  • V. V. Bueva
Article
  • 6 Downloads

Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.

Key Words

antidepressant GSB-106 preclinical pharmacokinetics HPLC-MS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bardakov AI, Litvin AA, Slivkin AI. Biopharmaceutical Approaches in the Development and Testing of Finished Dosage Forms. Voronezh, 2010. Russian.Google Scholar
  2. 2.
    Gribakina OG, Bochkov PO, Shevchenko RV, Zherdev VP. Validation of the method of quantitative HPLC/MS assay of GSB-106 compound in rat blood plasma. Eksp. Klin. Farmakol. 2018;81(S):60-61. Russian.Google Scholar
  3. 3.
    Zherdev VP, Boyko SS, Shevchenko RV, Gudasheva TA. The Role of pharmacokinetics and biopharmaceutical investigations in the creation of a new dipeptide drugs (experimental investigation). Farmakokinetika Farmakodinamika. 2017;(1):3-10. Russian.Google Scholar
  4. 4.
    Seredenin SB, Gudasheva TA. Patent RU No. 2410392. Dipeptide mimetics of NGF and BDNF neurotrophins. Bull. No. 3. Published January 27, 2011.Google Scholar
  5. 5.
    Kang HC, Huh KM, Bae YH. Polymeric nucleic acid carriers: current issues and novel design approaches. J. Control. Release. 2012;164(3):256-264.CrossRefGoogle Scholar
  6. 6.
    Kola I. The State of innovation in drug development. Clin. Pharmacol. Ther. 2008;83(2):227-230.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • G. B. Kolyvanov
    • 1
    Email author
  • V. P. Zherdev
    • 1
  • O. G. Gribakina
    • 1
  • P. O. Bochkov
    • 1
  • R. V. Shevchenko
    • 1
  • A. A. Litvin
    • 1
  • E. V. Blynskaya
    • 2
  • V. V. Bueva
    • 2
  1. 1.Laboratory of PharmacokineticsMoscowRussia
  2. 2.Laboratory of Finished Dosage Forms, V. V. Zakusov Research Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations